Lawrence Wrabetz archive

Research Expertise:

• Developmental Neurology
• Leukodystrophy

Research Centers:

• Center of Excellence in Bioinformatics and Life Sciences

UB 2020 Strategic Strengths:

• Molecular Recognition in Biological Systems and Bioinformatics

Grants and Sponsored Research: (selected)

• February 2019–January 2024
  NIH: The peripheral nervous system: a window into Krabbe disease
  Role: MPI
  $1,318,502
  
• January 2019–December 2020
  European Leukodystrophies Association (ELA): Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy.
  Role: Principal Investigator
  $79,443
• December 2018–November 2019
  NIH: Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy
  Role: Co-Investigator
  $250.000
• September 2016–June 2021
  NIH: The prohibitin family and their function in myelination and axonal health  
  Role: Co-Investigator
  $1,093,750
  
• October 2015–September 2017
  Empire State Development Corporation, The Research Foundation - Krabbe Disease Research Working Capital, Phase 6
  New York State
  Role: Principal Investigator
  $980,000
• May 2015–April 2019
  NIH: Enhancing Newborn Screening to Improve the Efficacy of Cord Blood Transplant for Krabbe Disease
  Role:  Co-Investigator
  $275,000
• October 2014–September 2015
  Empire State Development Corporation, The Research Foundation - Krabbe Disease Research Working Capital, Phase 5
  New York State
  Role: Principal Investigator
  $980,000
• October 2013–September 2014
  Empire State Development Corporation, The Research Foundation - Krabbe Disease Research Working Capital, Phase 4
  New York State
  Role: Principal Investigator
  $980,000
• October 2012–September 2013
  Empire State Development Corporation, The Research Foundation - Krabbe Disease Research Working Capital, Phase 3
  New York State
  Role: Principal Investigator
  $980,000
• October 2011–September 2012
  Empire State Development Corporation, The Research Foundation - Krabbe Disease Research Working Capital, Phase 2
  New York State
  Role: Principal Investigator
  $1,000,000
• October 2010–September 2011
  Empire State Development Corporation, The Research Foundation - Krabbe Disease Research Working Capital, Phase 1
  New York State
  Role: Principal Investigator
  $940,000
• September 2010–December 2013
  Telethon Program Project: Modulating Neuregulin-1 signals to treat hereditary demyelinating neuropathies
  Role: Principal Investigator
  $406,100
• April 2010–June 2015
  Empire State Development Corporation - Krabbe Disease Research Capital Equipment
  New York State
  Role: Principal Investigator
  $6,000,000
• February 2006–January 2012
  NIH: R01 NS055256 Pathogenesis of Myelin Protein Zero Neuropathies in Transgenic Mice
  Role: Principal Investigator
  $1,215,000
• February 2009–January 2011
  Fondazione Mariani: Side by Side analysis of children and mice with Myelin Protein Zero Neuropathies to promote treatment strategies
  Role: Principal Investigator
  $186,078
• September 2007–August 2010
  Telethon GGP07100: P0 glycoprotein trafficking and quality control in Charcot Marie Tooth 1B Neuropathy
  Role: Principal Investigator
  $487,654

Presentations:

• "Presentations: Oral Presentations/Symposia Chair by Invitation (selected):" (2013)
• "Pathogenesis in Hereditary Demyelinating Neuropathies: Toxic Mechanisms Target Development" Richard P. Bunge Memorial Lecture in Neuroscience; University of Miami (2013)
• "Endoplasmic Reticulum Stress and Translational Homeostasis in Myelinating Glia" Conference on Glia in Disease; University of Rochester; CTSI Symposium (2012)
• "ER Stress in Glia and Neurodegeneration"; University of Buffalo; Molecular Basis of Neurodegenerative Disorders (2012)
• "Preclinical Studies in Animals" Muscle Study Group Scientific Meeting (2012)
• "Pathogenesis in CMT Neuropathy versus Krabbe Leukodystrophy" 2nd Krabbe Translational Research Network; University of Pittsburgh (2012)
• "Toxic Mechanisms Impact Development in Hereditary Neuropathies"; Washington University School of Medicine; Department of Developmental Biology (2012)
• "Translational Homeostasis as a Therapeutic Target in CMT1B Neuropathy" 8th Great Lakes Glia Meeting (2011)
• "Translational Homeostasis as a Therapeutic Target in ER Stress Diseases" ISN Satellite Meeting on Myelin Biology (2011)
• "Translational Homeostasis as a Therapeutic Target in ER Stress Diseases" Translational Homeostasis as a Therapeutic Target in ER Stress Diseases (2011)
• "Genetic Background and CMT animal models" European Neuromuscular Center; Outcome Measures in Rodent Models of CMT (2011)
• "Translational Homeostasis as a Therapeutic Target in ER Stress Diseases" MRC Centre for Neuromuscular Diseases; University College London (2010)
• "Schwann cell pathways in inherited demyelinating neuropathies" World Federation of Neurology-XII International Congress on Neuromuscular Diseases; World Federation of Neurology-XII International Congress; Pathogenic Mechanisms of Inherited Neuropathies (2010)
• "Toxic Mechanisms in Hereditary Neuropathy" ISF-Legacy Heritage Fund Inaugural Meeting On New Approaches To Neurodegenerative Diseases (2010)
• "Endoplasmic reticulum stress impedes differentiation and translational homeostasis in hereditary demyelinating neuropathy"; CSIC Institute of Neuroscience; UMH (2009)
• "Altered translational control is pathogenetic in CMT1B mice"; Myelin Satellite to International Society for Neurochemistry (2009)
• "P0S63del impedes the arrival of wildtype P0 glycoprotein to myelin in CMT1B mice" CMT Meeting (2009)
• "Cell stress signals and peripheral neuropathy"; IFTZ Medizinische Universität (2008)
• "Packing defects or cell stress modulate hereditary demyelinating neuropathy"; University of Illinois (2008)
• Gordon Conference Myelin; Glial cell death and axonal pathology (2008)
• "Intracellular pathogenesis and phenotype in CMT neuropathies" Glial Cells in Health & Disease: The VIIIth European Meeting; The Molecular Pathology of Myelination (2007)
• "Inherited Neuropathies and Schwann cells" Peripheral Nerve Society Meeting (2007)
• "MTMR2 phospholipid phosphatase, CMT4B, and membrane trafficking in Schwann cells" Second European and North American Charcot-Marie-Tooth Consortium Meeting; Cell Biology of CMT (2007)
• "Endoplasmic reticulum stress and pathogenesis of CMT1B neuropathy" ; European Neurochemical Society; : Inherited Peripheral Neuropathies and Schwann cell Biology (2007)
• "Pathogenetic basis for phenotypic variation in CMT neuropathies" International Symposium on CMT neuropathies; German Congress for Muscle Pathology (2007)
• "Pathological Protein Quality Control in Hereditary Neuropathy" Director’s Seminar Series; National Institute of Neurological Disorders and Stroke; NIH (2006)
• "Pitfalls of Translational Research for Genetic Diseases—The Plus and Minus of Animal Models" Translational Research Forum; National Institute of Neurological Disorders and Stroke; NIH (2006)
• "Transgenic Mouse Models of Phenotypic Diversity in Hereditary Demyelinating Neuropathies"; University of Torino; University of Torino (2006)
• "Unfolded Protein Response: A Cause for demyelinating Charcot Marie Tooth Neuropathy" Interdepartmental Seminar Series; University of Bonn (2006)
• "ER Stress Modulates Demyelinating CMT Neuropathy in Transgenic Mice"; Albert Einstein School of Medicine; Department of Neuroscience (2006)
• "Myelin Protein Zero trafficking and quality control in Charcot-Marie-Tooth neuropathies" Myelin Gordon Conference (2006)
• "Intracellular pathogenesis of childhood-onset hereditary neuropathies"; University of Antwerp (2006)
• "Intracellular pathogenesis of childhood-onset hereditary neuropathies" Research advances in developmental neurosciences and paediatric neurology; Congress of the European Academy of Childhood Disability (2005)
• "Protein Quality Control of P0 Glycoprotein in Hereditary Neuropathies" Jordi Folch-Pi Memorial Symposium; American Society for Neurochemistry; Progress on the pathogenesis of hereditary neurodegenerative disorders (2005)
• "Gain of abnormal function and phenotypic diversity in MPZ-related neuropathies" Second Annual Symposium of the North American Charcot-Marie-Tooth Consortium; Ann Lee Beyer Plenary Lecture (2005)
• "Protein quality control in the pathogenesis of CMT1B hereditary neuropathy" Dutch Endo-Neuro-Psycho Meeting (2005)
• "Importance of defined genetic background to experimental design"; Charles River Laboratories European Short Course (2005)
• "Protein Quality Control of P0 Glycoprotein in Mouse Models of Hereditary Neuropathies"; Vienna BioCenter (IBMA, IMP & Univ Vienna) and Austrian Society of Genetics (2004)
• "Transgenic mouse models of CMT1B neuropathy reveal gain of abnormal Mpz function" First European and North American Charcot-Marie-Tooth Consortium Meeting; CMT type 1B and MPZ (2004)
• "Genetic Nomenclature, Defined Strains and Experimental Design" ; Charles River Laboratories/The Jackson Laboratory Course; Setting the gold standard in genetics (2004)
• "Genotype, phenotype and mechanism comparisons in transgenic mouse models of hereditary neuropathies"; IBRO Congress (2003)
• "Schwann cell biology: from developmental mechanisms to pathological processes"; IBRO Congress (2003)
• "Transgenic mouse models of hereditary neuropathy" UK Glial Club Meeting (2003)
• "Trangenic mice model diversity in hereditary neuropathies"; European School of Medical Genetics (2002)
• "Proteomics on transgenic optic nerve" Franco-Italian Meeting on MS (2001)
• "Axoglial signals target the myelin basic protein promoter" INSERM; Hopital 
   de la Salpetriere (2000)
• "Epitope tagged-P0 glycoprotein in transgenic mice causes CMT1B-like neuropathy" ; Society for Neuroscience (2000)
• "Gain of P0 glycoprotein function: Mouse models of diverse hereditary neuropathies" ; University of Edinburgh (2000)
• "Gain of P0 function: Mouse models of hereditary neuropathies" Gordon Conference on Myelin (2000)
• "From stem cells to glia: molecules and mechanisms" UK Glial Cell Club Meeting (2000)
• "P0 overexpression causes congenital hypomyelination in transgenic mice" Telethon Scientific Convention (1999)
• "A distinct axonal signal regulates MBP transcription during CNS myelinogenesis" Society for Neuroscience (1999)
• "Regulation of MBP transcription during CNS myelinogenesis: the role of axons" British Neuroscience Association Meeting (1999)
• "P0 gene dosage and mouse models of CMT1B" Third International Conference on Charcot-Marie-Tooth Disorders (1998)
• "Increased P0 glycoprotein gene dosage causes a dysmyelinating peripheral neuropathy in transgenic mice" Gordon Conference on Myelin (1998)
• "Normal PNS myelination depends on precise dosage of the P0 glycoprotein gene" Armenise-Harvard Symposium (1997)
• "Transgenic mouse model of remyelination" Remyelination in Multiple Sclerosis; European Charcot Foundation Symposium (1996)
• "Normal PNS myelination depends on precise dosage of the P0 glycoprotein gene" Armenise-Harvard Symposium

• July 2020, Research clarifies cellular mechanisms in Krabbe Fight
• May 2020, UB investigators uncover cellular mechanism involved in Krabbe disease
• May 2019, Pursuing New Direction to Understand Krabbe Disease
  
• March 2019, Congressman Higgins Announces Over $2M in Federal Funding to Support Krabbe Disease Research at the Hunter James Kelly Research Institute at UB
• October 2018, MD-PhD Student Awarded Prestigious NIH Fellowship
• Summer 2017, Such Opportunities are Rare: Unique Program Draws Top Myelin Researchers to Buffalo,
• April 2015, New candidate drug ‘dials down’ protein synthesis to treat demyelinating diseases
• July 2014, Vision, Neurology Experts Name UB Distinguished Professors
• January 2014, UB Chosen to Co-Lead Major State Effort to Spur Genome Research
• May 2013, Researchers ID Neuropathy Cause, Restore Myelination
• September 2012, Postdoctoral Biochemist Awarded $40,000 Neuropathy Fellowship
• November 2011, Arrival of Wrabetz and Feltri moves work of Kelly institute forward
• August 2010, Noted Researchers join Kelly Institute